Evidence for the abundant expression of arginine 185 containing human CRF2α receptors and the role of position 185 for receptor-ligand selectivity

被引:23
作者
Dautzenberg, FM [1 ]
Huber, G [1 ]
Higelin, J [1 ]
Py-Lang, G [1 ]
Kilpatrick, GJ [1 ]
机构
[1] F Hoffmann La Roche & Co Ltd, Div Pharma, CH-4070 Basel, Switzerland
关键词
receptor expression; ligand binding; RT-PCR; genomic structure;
D O I
10.1016/S0028-3908(00)00044-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The abundance of a histidine residue at position 185 (His(185)) of the human corticotropin-releasing factor (CRF) type 2 alpha receptor (hCRF(2 alpha)) was investigated. His(185) has only been reported in hCRF(2); CRF2 proteins from other species and all CRF1 receptors encode an arginine (Arg(185)) at the corresponding position. Cloning of partial and full-length hCRF(2) cDNAs from a variety of neuronal and peripheral tissues revealed the existence of receptor molecules encoding Arg(185) only. Sequence analysis of the hCRF2 gene verified the existence of Arg(185) also on genomic level. Full-length cDNAs encoding either the His(185) (R2H(185)) or the Arg(185) (R2R(185)) variants of hCRF(2 alpha) were stably expressed in HEK293 cells and tested for ligand binding properties. In displacement studies R2H(185) and R2R(185) displayed a similar substrate specificity, human and rat urocortin, and the peptide antagonists astressin and alpha-helical CRF(9-41) were bound with high affinity whereas human and ovine CRF were low-affinity ligands. Significant differences were observed for sauvagine and urotensin I, which bound with 3-fold (sauvagine) and 9-fold (urotensin I) higher affinity to R2R(185). These data indicate that hCRF(2), like all vertebrate CRF1 and CRF2 proteins encodes an arginine residue at the junction between extracellular domain 2 and transmembrane domain 3 and that this amino acid plays a role fur the discrimination of some CRF peptide ligands. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1368 / 1376
页数:9
相关论文
共 25 条
[1]   The role of corticotropin-releasing factor in depression and anxiety disorders [J].
Arborelius, L ;
Owens, MJ ;
Plotsky, PM ;
Nemeroff, CB .
JOURNAL OF ENDOCRINOLOGY, 1999, 160 (01) :1-12
[2]   Human CRF2 α and β splice variants:: pharmacological characterization using radioligand binding and a luciferase gene expression assay [J].
Ardati, A ;
Goetschy, V ;
Gottowick, J ;
Henriot, S ;
Valdenaire, O ;
Deuschle, U ;
Kilpatrick, GJ .
NEUROPHARMACOLOGY, 1999, 38 (03) :441-448
[3]  
Dautzenberg FM, 1999, J NEUROENDOCRINOL, V11, P941
[4]  
Dautzenberg FM, 1997, J NEUROCHEM, V69, P1640
[5]   Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1:: Implications for the ligand-binding site [J].
Dautzenberg, FM ;
Wille, S ;
Lohmann, R ;
Spiess, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :4941-4946
[6]   The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: Generation of chimeric receptors with a novel ligand-selective profile [J].
Dautzenberg, FM ;
Kilpatrick, GJ ;
Wille, S ;
Hauger, RL .
JOURNAL OF NEUROCHEMISTRY, 1999, 73 (02) :821-829
[7]   Cloning and characterization of human urocortin [J].
Donaldson, CJ ;
Sutton, SW ;
Perrin, MH ;
Corrigan, AZ ;
Lewis, KA ;
Rivier, JE ;
Vaughan, JM ;
Vale, WW .
ENDOCRINOLOGY, 1996, 137 (05) :2167-2170
[8]   PHYSIOLOGICAL AND BEHAVIORAL-RESPONSES TO CORTICOTROPIN-RELEASING FACTOR ADMINISTRATION - IS CRF A MEDIATOR OF ANXIETY OR STRESS RESPONSES [J].
DUNN, AJ ;
BERRIDGE, CW .
BRAIN RESEARCH REVIEWS, 1990, 15 (02) :71-100
[9]   POTENT, STRUCTURALLY CONSTRAINED AGONISTS AND COMPETITIVE ANTAGONISTS OF CORTICOTROPIN-RELEASING FACTOR [J].
GULYAS, J ;
RIVIER, C ;
PERRIN, M ;
KOERBER, SC ;
SUTTON, S ;
CORRIGAN, A ;
LAHRICHI, SL ;
CRAIG, AG ;
VALE, W ;
RIVIER, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10575-10579
[10]  
Hauger RL, 1997, J NEUROCHEM, V68, P2308